SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Oron Assaf

(Last) (First) (Middle)
C/O BIOMX INC., 22 EINSTEIN ST., FLOOR 4

(Street)
NESS ZIONA, L3 7414003

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BiomX Inc. [ PHGE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Business Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/29/2023
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Common Stock Options - Right to Buy $1.691 10/29/2023 D(1) 155,363 (1) 03/26/2027 Common Stock 0 $0 0 D
Common Stock Options - Right to Buy $0.275 10/29/2023 A(1) 155,363 (1) 03/26/2027 Common Stock 0 $0 0 D
Common Stock Options - Right to Buy $1.973 10/29/2023 D(2) 82,667 (2) 05/22/2028 Common Stock 0 $0 0 D
Common Stock Options - Right to Buy $0.275 10/29/2023 A(2) 82,667 (2) 05/22/2028 Common Stock 0 $0 0 D
Common Stock Options - Right to Buy $2.031 10/29/2023 D(3) 46,966 (3) 03/29/2029 Common Stock 0 $0 0 D
Common Stock Options - Right to Buy $0.275 10/29/2023 A(3) 46,966 (3) 03/29/2029 Common Stock 0 $0 0 D
Explanation of Responses:
1. The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 03/26/2017 and provides for vesting over four years, with 25% of the shares subject to the option vested on 03/26/2018, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.
2. The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 05/22/2018 and provides for vesting over four years, with 25% of the shares subject to the option vested on 05/22/2019, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.
3. The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 03/29/2019 and provides for vesting over four years, with 25% of the shares subject to the option vested on 03/29/2020, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.
/s/ Assaf Oron 10/31/2023
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

BiomX (AMEX:PHGE)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024 Plus de graphiques de la Bourse BiomX
BiomX (AMEX:PHGE)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024 Plus de graphiques de la Bourse BiomX